PROGRAM MENU
Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2022 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.


  Mon - Aug 15      Tue - Aug 16      Wed - Aug 17      Thu - Aug 18   

THURSDAY, AUGUST 18

6:45 - 7:45 AM
SATELLITE SYMPOSIUM
EMERGING STRATEGIES IN HEMOPHILIA: RESTORING THE HEMOSTATIC BALANCE (SPONSORED BY CLINICAL CARE OPTIONS, LLC)
Chicago Ballroom VI

The 1. 0-hour, CME-certified satellite symposium will include an engaging discussion on the management of hemophilia A and B. Expert faculty will use case discussions to highlight the challenges with factor VIII and factor IX replacement, the health burden of hemophilia care, and the need for more novel treatments. In addition, faculty will cover the future of hemophilia therapy, which includes novel therapies aimed at restoring hemostatic balance by blocking/targeting the tissue factor pathway inhibitor or antithrombin. The symposium will close with a panel discussion of key abstracts on hemophilia management from THSNA 2022 and an audience question and answer session.



RAISING THE BAR FOR PEOPLE WITH HEMOPHILIA AND INHIBITORS: CLINICIAN AND PATIENT PERSPECTIVES ON ACUTE BLEED MANAGEMENT WITH EPTACOG BETA (SPONSORED BY HEMA BIOLOGICS)
Chicago Ballroom IX-X

Inhibitor development remains the most serious complication of hemophilia A or B treatment, causing significant burden on the patient, their family, providers, and the healthcare system. Abundant prophylaxis and bleed treatment options exist for hemophilia patients without inhibitors, bringing health equity within reach. For patients with inhibitors, however, acute bleed management has lagged. Even for those on prophylaxis with non-replacement therapies, spontaneous and traumatic bleeding events are still a reality. Having different options for both prophylaxis and bleed control empowers clinicians to individualize and tailor treatment regimens, providing patients with opportunities to improve their clinical outcomes and pursue their life goals. The objectives of therapy are enabling individuals with inhibitors to participate in their life in the manner that they choose, and not be limited by their disease or by the treatment of their disease. Join a panel of experts, including an individual with hemophilia A and inhibitors, to discuss their clinical experience with eptacog beta and its contribution towards achieving health equity in patients with hemophilia A or B with inhibitors. The discussion will be moderated by Leonard A. Valentino, MD, and feature a subject matter expert who has thrived despite inhibitors, and Robert Sidonio Jr, MD.


8:00 - 9:30 AM
THROMBOSIS
HORMONE THERAPY AND THROMBOSIS-HOT TOPICS IN SEX AND GENDER RELATED THROMBOSIS
Chair/Organizer: Vinai Bhagirath, Megan Brown
Sheraton Ballroom IV-V


8:00

ANTICOAGULANTS AND MENSTRUAL BLEEDING
Bethany Samuelson Bannow. Oregon Health a Science University


8:25

ANTICOAGULATION OF MECHANICAL HEART VALVES IN PREGNANCY
Rohan D'Souza. McMaster University


8:50

COAGULATION AND TRANSGENDER PATIENTS
Nicoletta Machin.


9:15

Q&A.

8:00 - 9:30 AM
LABORATORY
INHIBITOR TESTING ISSUES
Chair/Organizer: Parul Bhargava, Bhavya Doshi
Chicago Ballroom VII


8:00

STANDARDIZATION EFFORTS AND ISSUES WITH MIXING STUDIES
Bob Gosselin. Hemostasis a Thrombosis Center, UC Davis Health System


8:25

TESTING IN ACQUIRED FACTOR VIII INHIBITORS
Marian Rollins-Raval. University of New Mexico


8:50

CHALLENGES IN LABORATORY DIAGNOSIS OF LUPUS ANTICOAGULANTS
Katrien Devreese. Ghent University Hospital, Ghent University


9:15

Q&A.

8:00 - 9:30 AM
HEMOSTASIS / BASIC SCIENCE
PAIN SCIENCE IN BLEEDING DISORDERS
Chair/Organizer: Michelle Witkop, Maria E Santaella
Sheraton Ballroom I-III


INTRODUCTION VIDEO.


8:00

ROLE OF FACTOR VIII IN NEUROPATHOLOGY OF HEMOPHILIA A
Janice Staber. University of Iowa Stead Family Children's Hospital


8:25

CLINICAL ASPECTS OF PAIN IN BLEEDING DISORDERS
Kim Mauer. OHSU


8:50

BENCH TO BEDSIDE: COMPLEMENTARY APPROACHED AND STRATEGIES TO DEVELOP MECHANISM BASED TARGETS FOR PAIN MANAGEMENT AND TREATMENT
Kalpna Gupta. Professor, University of California, Irvine


9:15

Q&A.

9:30 - 10:00 AM
POSTERS/EXHIBITS/BREAK
Ballroom Promenade

10:00 - 11:00 AM
SHORT TALKS
SHORT TALKS - BLEEDING III
Chair/Organizer: Robert Sidonio, John Chiari
Sheraton Ballroom I-III


10:00

PREVALENCE AND CLINICAL CHARACTERISTICS OF JOINT BLEEDS IN THOSE PRESENTING WITH MILD HEMOPHILIA
John B. Chiari BS1, Stephanie Prozora, MD2, Patrick G. Gallagher, MD2, Robert Bona, MD3. 1Frank H. Netter MD School of Medicine, Quinnipiac University, North Haven, CT, USA. 2Yale University, Department of Pediatrics, New Haven, CT, USA. 3Yale University, Department of Internal Medicine/Hematology, New Haven, CT, USA


10:12

POSTOPERATIVE BLEEDING OUTCOMES IN PATIENTS WITH COAGULATION FACTOR DEFICIENCIES
Marina J. Heskel, Stephanie Prozora, Jennifer Cornell, Kristina Selander, Evangelia Louizos, Patrick G. Gallagher, Robert Bona. Yale University School of Medicine, New Haven, CT, USA


10:24

RETROSPECTIVE COHORT ANALYSIS OF DDAVP CHALLENGE OUTCOMES IN PEDIATRIC VON WILLEBRAND DISEASE: EVALUATION BY PATIENT BLOOD GROUP AND DISEASE SUBTYPE
Caroline Malcolmson1, 2, Amanda Fregonas1, Bryan Maguire1, Tristan Knight1, Vanessa Bouskill1, 2, Manuel Carcao1, 2. 1Hospital for Sick Children, Toronto, ON, Canada. 2University of Toronto, Toronto, ON, Canada


10:36

ROLE OF A MULTIDISCIPLINARY “PERIOD CLINIC” FOR MANAGEMENT OF ADOLESCENTS WITH ABNORMAL UTERINE BLEEDING - A SINGLE INSTITUTION EXPERIENCE
Blaire Taggart1, Divyaswathi Citla-Sridhar2, Laura Hollenbach3, Shelley Crary2. 1MD/MPH Candidate, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 2 Division of Pediatric Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 3Division of Pediatric and Adolescent Gynecology, University of Arkansas for Medical Sciences, Little Rock, AR, USA


SHORT TALKS - PLATELETS, LEUKOCYTES & INFLAMMATION
Chair/Organizer: Anh T. Ngo, Kristi Smock
Chicago Ballroom VII


10:00

PLASMA PROTEOMIC PROFILING IDENTIFIES UNIQUE SIGNATURES OF ENDOTHELIAL ACTIVATION AND INFLAMMATION UNDERLYING PROGNOSTIC MARKERS OF HYPERCOAGULATION IN ALCOHOLIC CIRRHOSIS
Cecily Allen1, Ayesha Butt2, Parveen Bahel3, C-Hong Chang4, Hyung J Chun4, Sean Gu4, John Hwa4, Sofia S Jakab5, Matthew J McConell5, Henry Rinder3, Uyen To5, Robert Bona2, Alfred I Lee2, Alexander B Pine2. 1Internal medicine residency, Yale New Haven Hospital, New Haven, CT, USA. 2Section of Hematology, Yale School of Medicine, New Haven, CT, USA. 3Department of Laboratory Medicine, Yale New Haven Hospital/Yale School of Medicine, New Haven, CT, USA. 4Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, New Haven, CT, USA. 5Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, USA


10:12

GENETIC ABLATION OF MITOCHONDRIAL CALCIUM UNIPORTER B INHIBITS PLATELET FUNCTION AND ARTERIAL THROMBOSIS
Madankumar Ghatge, Manasa K Nayak, Gagan Flora, Neelam Chauhan, Rakesh B Patel, Anisha Mehra, Nirav Dhanesha, Yuriy Usachev, Anil K Chauhan. Division of Hematology/Oncology, Department of Internal Medicine, Iowa City, IA, USA


10:24

TOXICITY OF NEUTROPHIL EXTRACELLULAR TRAPS (NETS) AND THE EFFECTS OF PLATELET FACTOR 4 (PF4) ON NET THROMBOGENICITY: THERAPEUTIC IMPLICATIONS
Anh T. Ngo1, Amrita Sarkar1, Irene Yarovoi1, Guohua Zhao1, Lubica Rauova1, 2, M. Anna Kowalska1, Mortimer Poncz1, 2, Kandace Gollomp1, 2. 1Division of Hematology, Children, Philadelphia, PA, USA. 2Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA


10:36

BIOMARKERS OF THROMBOINFLAMMATION IN HOSPITALIZED PATIENTS WITH COVID-19 INFECTION
Meera Sridharan, Taleen MacArthur, Julie Goswami, Julie Tange, Serena Navitskas, Elizabeth Kock, Damon Houghton, Myung Park, Nahla Heikal, Dong Chen, Rajiv Pruthi. Mayo Clinic, Rochester, MN, USA


SHORT TALKS - THROMBOSIS CLINICAL AND SCIENCE II
Chair/Organizer: Katrien Devreese, Conroy O Field
Sheraton Ballroom IV-V


10:00

RISK OF RECURRENT THROMBOSIS IN PATIENTS WITH SINGLE POSITIVE ANTIPHOSPHOLIPID SYNDROME
Brianna R Bakow1, Shruti Chaturvedi2. 1Division of Hematology/Oncology, Warren Alpert Medical School of Brown University, Providence, RI, USA. 2Division of Hematology/Oncology, Johns Hopkins University, Baltimore, MD, USA


10:12

VENOUS THROMBOEMBOLISM IN PATIENTS WITH INHERITED THROMBOPHILIA AFTER COVID-19 VACCINATION
Damon Houghton1, Ana Casanegra1, Waldemar Wysokinski1, Leslie Padrnos2, Surbhi Shah2, Ewa Wysokinska1, Padmanabhan Anand1, McBane Robert1. 1Mayo Clinic, Rochester, MN, USA. 2Mayo Clinic, Scottsdale, AZ, USA. 3Mayo Clinic, Jacksonville, FL, USA


10:24

DOAC COMPARED WITH WARFARIN FOR VTE IN PATIENTS WITH OBESITY: A RETROSPECTIVE COHORT STUDY CONDUCTED THROUGH THE VENUS NETWORK
Karlyn A Martin1, Nicola Lancki1, Celina Li2, M. Elaine Eyster3, Kristen Sanfilippo4, Scott Woller5, 6, Rachel P Rosovsky2, Lisa Baumann Kreuziger7, 8. 1Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 2Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA. 3Penn State College of Medicine, Hershey, PA, USA. 4Washington University School of Medicine and St. Louis Veterans Administration Medical Center, St. Louis, MO, USA. 5University of Utah, Salt Lake City, UT, USA. 6Intermountain Medical Center, Murray, UT, USA. 7Medical College of Wisconsin, Milwaukee, WI, USA. 8Versiti Blood Research Institute, Milwaukee, WI, USA


10:36

REAL-WORLD CLINICAL OUTCOMES AMONG US VETERANS WITH ORAL FACTOR XA INHIBITOR-RELATED MAJOR BLEEDING TREATED WITH ANDEXANET ALFA OR 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE
S. Scott Sutton1, Joe Magagnoli1, Tammy H. Cummings1, Terry Dettling2, James Hardin3, Belinda Lovelace2. 1Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA. 2Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, SC, USA. 3Alexion, AstraZeneca Rare Disease, Boston, MA, USA


10:48

RISK FACTORS FOR MISSED DOSES OF PHARMACOLOGIC VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS IN TRAUMA PATIENTS: A MULTICENTER PROSPECTIVE STUDY
Mujan Varasteh Kia1, Christine Holzmueller2, Michael Streiff1, Peggy Kraus2, Oluwafemi Owodunni1, Brandyn Lau1, Dauryne Shaffer1, Stephanie Armocida1, Elliott Haut1. 1Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2Johns Hopkins Medicine, Baltimore, MD, USA

11:05 - 12:20 PM
PLENARY SESSION
ON THE CUTTING EDGE OF HEMOSTASIS AND THROMBOSIS
Chair/Organizer: Kristi Smock, Anne Rose
Sheraton Ballroom IV-V


INTRODUCTION VIDEO.


11:05

FUTURE OF THERAPY FOR FACTOR DEFICIENCIES
Guy Young. Children's Hospital Los Angeles


11:25

FUTURE OF ANTICOAGULATION THERAPIES FOCUSING ON TARGETS
Jeff Weitz. McMaster University


11:45

ANTIBODIES IN HITT AND VITT
Ishac Nazy. McMaster University


12:05

Q&A.